Join us for Meet With…Johnson & Johnson’s Immunology Team at JLABS @ Washington, DC on May 21.
During Digestive Disease Week 2024, our Johnson & Johnson Immunology Team will present our strategic priorities in the space as part of our search for promising scientific innovations in the following areas: differentiated MOAs with potential for gut barrier restoration, patient stratification or use in combination regimes, and orals for clinically validated targets.
J
WASHINGTON–(BUSINESS WIRE)–Nanochon, a Washington, DC-based orthopedic device biotech company has raised $4 million in its series seed prime fundraising round.
The round was led by The University of Virginia Licensing and Ventures Group Seed Fund, with participation from Cultivate (MD), Alumni Venture Group, and Mountain State Capital, among others.
Nanochon intends to use the funds to initiate its first in human clinical trials in the US in 2024, deepen research and development efforts, expand the company’s patent profile and grow its team.
welldoc® recently presented a new clinical research paper at the 14th annual Conference on Health IT and Analytics (CHITA) in Washington, D.C. This research focuses on the latest advancements in artificial intelligence and weight management, areas of significant interest across the healthcare industry.
Hosted by the Center for Digital Health and Artificial Intelligence (CDHAI) at the Johns Hopkins Carey School of Business, CHITA explores innovative developments in the design, implementation, and management of health information technology and analytics.
Welldoc’s presentation, authored by Abhi Kumbara, Anand Iyer, and Mansur Shomali in collaboration with their colleagues from Johns Hopkins CDHAI, is now available on their website.
BETHESDA, Md., May 06, 2024 (GLOBE NEWSWIRE) — AsclepiX Therapeutics, Inc., a clinical-stage biopharmaceutical company leveraging computational biology from Johns Hopkins to identify and develop peptides for improved treatments of retinal diseases, today announced the completion of enrollment into the DISCOVER trial (NCT05859776). Fifteen patients have completed enrollment in the trial for AXT107 (gersizangitide). The objectives of the trial are to evaluate the safety and tolerability of three dose strengths of AXT107 [125 µg (n=3), 250 µg (n=3), and 500 µg (n=9)] and to determine the bioactivity and duration of action when injected suprachoroidally. Secondary endpoints will include efficacy as assessed by central subfield thickness (CST) and best-corrected visual acuity (BCVA). Following a single injection of AXT107, to date, no patient has shown any remarkable safety findings.
ROCKVILLE, Md.–(BUSINESS WIRE)–GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced topline results from its Phase 3 global pivotal study of uproleselan in 388 patients with R/R AML. In the study, uproleselan combined with chemotherapy did not achieve a statistically significant improvement in overall survival in the intent to treat population versus chemotherapy alone.
Patients treated with uproleselan had a median overall survival of 13 months, compared to 12.3 months in the placebo arm. Adverse events were consistent with known side effect profiles of chemotherapy used in the study.
FREDERICK, MD, UNITED STATES, May 1, 2024 /EINPresswire.com/ — BioSolution Designs is pleased to announce the formation of its first drug development subsidiary, BeatBio, created to develop complex multigenic therapeutics for cardiovascular diseases.
The company, headquartered in Cincinnati, is led by Thomas D Reed, PhD, who previously co-developed a multigenic plasmid DNA (pDNA) gene therapy (INXN-4001) at Triple-Gene, a cardiovascular gene therapy subsidiary of Intrexon (now Precigen – PGEN), which showed a functional improvement in 50 percent of heart failure patients after a single dose in early human testing.
BeatBio will deploy BioSolution Designs’ proprietary Bird of PreyTM multigenic design and assembly system to develop complex therapies to treat cardiovascular and peripheral artery disease. The highly-engineered yet easy-to-use platform enables faster and cheaper design and assembly of a “library” of complex vectors, for screening multiple genetic combinations to prioritize the best therapeutic candidates.
The ARPA-H Sprint for Women’s Health is a funding opportunity to address critical unmet challenges in women’s health, championing transformative innovations and tackling health conditions that uniquely or disproportionately affect women. ARPA-H is committing $100 million to this effort and is using two funding tracks, spark (early-stage research) and launchpad (later-stage development), to foster transformative research and development efforts.
ARPA-H had an unprecedented response of submissions, representing 45 states, the District of Columbia, and 34 countries, received from a mix of scientific visionaries from across the globe and sectors. More than half of those submissions came from organizations with less than 50 people. Proposals covered the six topics, including the wild card, and innovative ideas ranged from novel, groundbreaking research to opportunities to accelerate and scale tools, products, and platforms with potential for commercialization.
May 2, 2024, Emily Wishingrad, Washington, D.C.
Maryland’s life sciences market, one of the largest in the country, has a lot of things going for it — a hearty talent pipeline, federal research agencies and relatively cheap real estate prices.
One thing that it doesn’t have pinned down quite yet: the urban, mixed-use, flexible developments that are most attractive to today’s tenants.
Local leaders and industry executives at Bisnow’s Mid-Atlantic Life Sciences and Biotech Summit last week said that for the area to keep up with its peer markets like Boston-Cambridge and San Diego, developers need to start thinking outside the traditional life sciences box.
Frederick, MD, May 2, 2024 – BioSolution Designs (BSD), a biotechnology invention studio developing proprietary platforms for multigenic gene and cell therapies, today announced its ongoing strategic collaboration with RoosterBio, a leading provider of human mesenchymal stem/stromal cells (MSCs), highly engineered media solutions, and bioprocess development services.
This partnership leverages BSD’s multigenic design and assembly platform, Bird of Prey™, and cell engineering expertise along with RoosterBio’s cutting-edge MSC and exosome bioprocessing products, manufacturing protocols, and analytical services to simplify the development and manufacturing of engineered MSC derived therapies.
Venlo, the Netherlands, April 29, 2024 (GLOBE NEWSWIRE) — QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced results for the first quarter of 2024.
Net sales declined 5% to $459 million, while results at constant exchanges rates (CER) of $462 million were above the outlook for at least $455 million CER. The adjusted operating income margin rose to 25.7% from 25.6% in the year-ago period on realized efficiency gains while supporting investments into the portfolio. Adjusted diluted earnings per share (EPS) were $0.46, and results at CER were $0.47 and above the outlook for at least $0.44 CER.
For 2024, QIAGEN has reaffirmed its outlook for net sales of at least $2.0 billion CER. Adjusted diluted EPS are expected to be at least $2.10 CER, led by the adjusted operating income margin rising to above 28% of sales for FY 2024 compared to 26.9% in 2023 while supporting investments.
